TECARTUSHCP.COM: Keyword Density Checker

Total words: 5179 | 2-word phrases: 1324 | 3-word phrases: 1579 | 4-word phrases: 1697

PAGE INFO

Title	Try to keep the title under 60 characters (63 characters) CAR T for R/R MCL and R/R B-cell ALL \| TECARTUS® HCP Website
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	patients with all	13	0.82%
2	of patients with	10	0.63%
3	patients with mcl	10	0.63%
4	relapsed or refractory	8	0.51%
5	with relapsed or	8	0.51%
6	adult patients with	7	0.44%
7	modified autologous t	7	0.44%
8	treatment with tecartus	7	0.44%
9	patients with relapsed	6	0.38%
10	days range 1	6	0.38%
11	range 1 to	6	0.38%
12	time to onset	5	0.32%
13	after tecartus infusion	5	0.32%
14	mantle cell lymphoma	5	0.32%
15	days for patients	5	0.32%
16	autologous t cell	5	0.32%
17	a cd19directed genetically	5	0.32%
18	is a cd19directed	5	0.32%
19	median time to	5	0.32%
20	with mcl and	4	0.25%
21	following treatment with	4	0.25%
22	≥ grade 3	4	0.25%
23	mcl and all	4	0.25%
24	cytokine release syndrome	4	0.25%
25	the median time	4	0.25%
26	3 or higher	4	0.25%
27	refractory bcell precursor	4	0.25%
28	for patients with	4	0.25%
29	tecartus® brexucabtagene autoleucel	4	0.25%
30	for the treatment	4	0.25%

#	Keyword	Frequency	Density
1	with relapsed or refractory	7	0.41%
2	patients with relapsed or	6	0.35%
3	days range 1 to	6	0.35%
4	adult patients with relapsed	6	0.35%
5	of patients with all	5	0.29%
6	is a cd19directed genetically	5	0.29%
7	of patients with mcl	5	0.29%
8	modified autologous t cell	5	0.29%
9	median time to onset	5	0.29%
10	the median time to	4	0.24%
11	relapsed or refractory mantle	4	0.24%
12	immunotherapy indicated for the	4	0.24%
13	indicated for the treatment	4	0.24%
14	or refractory mantle cell	4	0.24%
15	refractory mantle cell lymphoma	4	0.24%
16	patients with mcl and	4	0.24%
17	days for patients with	4	0.24%
18	not resolved by day	3	0.18%
19	following treatment with tecartus	3	0.18%
20	days with a median	3	0.18%
21	overall response rate and	3	0.18%
22	cytopenias not resolved by	3	0.18%
23	tecartus® brexucabtagene autoleucel is	3	0.18%
24	grade 3 or higher	3	0.18%
25	for patients with all	3	0.18%
26	under accelerated approval based	3	0.18%
27	relapsed or refractory bcell	3	0.18%
28	or refractory bcell precursor	3	0.18%
29	refractory bcell precursor acute	3	0.18%
30	days range 2 to	3	0.18%
31	brexucabtagene autoleucel is a	3	0.18%
32	signs and symptoms of	3	0.18%
33	for signs and symptoms	3	0.18%
34	accelerated approval based on	3	0.18%
35	response rate and durability	3	0.18%
36	approved under accelerated approval	3	0.18%
37	genetically modified autologous t	3	0.18%
38	is approved under accelerated	3	0.18%
39	of adult patients with	3	0.18%
40	autologous t cell immunotherapy	3	0.18%

#	URL	Whois	Check
1	https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf	Whois	gilead.com
2	https://yescartatecartusrems.com	Whois	yescartatecartusrems.com
3	https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf	Whois	gilead.com
4	https://www.kitepharma.com/terms-of-use	Whois	kitepharma.com
5	https://www.kitepharma.com/privacy-policy/	Whois	kitepharma.com
6	https://www.kitepharma.com/consumer-health-data-privacy-policy	Whois	kitepharma.com
7	https://www.gilead.com/contact	Whois	gilead.com
8	https://www.yescartatecartusrems.com/	Whois	yescartatecartusrems.com